Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Bayer : helping people affected by the earthquake in Mexico

share with twitter share with LinkedIn share with facebook
share via e-mail
10/03/2017 | 01:45pm CEST

Release date- 29092017 - Leverkusen - As part of its disaster relief program, Bayer is donating medicines worth EUR 268,000 to the victims of the major earthquake that struck Mexico.

This aid will offer speedy and unbureaucratic relief to the people affected by this tragedy in Central America. The medicines will be sent to the non-profit organization Direct Relief for distribution to people injured in the quake. Direct Relief is a long-term strategic partner of Bayer that provides assistance and medical supplies around the world to regions torn by crisis and areas with limited medical access. Mexico City was hit by a magnitude 7.1 earthquake on September 19, 2017, and hundreds of people perished.

Providing disaster relief is part of Bayer's social commitment. The company follows a dual strategy to help people affected by acute hardship: When disaster strikes, Bayer provides immediate assistance - either by donating money and medicines or making material donations to help rebuild infrastructure. In addition, Bayer AG's charitable foundation, the Bayer Cares Foundation, supports long-term reconstruction projects.

In 2017, Bayer has already provided support to projects in the following nine regions affected by disasters: The Brazilian organization Mundo Positivo received a donation of EUR 203,000 to implement a preventive program in the state of Pernambuco, which has been hit by the Zika virus. The Canadian Red Cross received EUR 14,000 to combat devastating wildfires in rural areas. The organization Direct Relief and the American Red Cross received EUR 93,000 each to provide rapid assistance to people in the U.S. state of Texas, one of the areas hit by Hurricane Harvey. The Chilean fire service received EUR 92,000 to initiate a family protection program. Medicines were donated to the CDC Foundation for distribution to young women attending prenatal visits in Puerto Rico, one of the countries affected by the Zika virus (worth EUR 56,000); the Colombian Civil Air Patrol to assist people affected by flooding in Mocoa (EUR 24,000) and U.S. animal welfare organizations to help care for pets and livestock injured by Hurricane Harvey (EUR 24,000). The Nigerian Ministry of Agriculture also received plant protection products worth EUR 30,000 for smallholder farmers to use to treat crops infested with armyworm moths. In total, ten projects have now received donations of money or products totaling around EUR 897,000.

Bayer Cares Foundation

As the social welfare foundation of the innovation company Bayer, the Bayer Cares Foundation sees itself especially as an initiator, promoter and partner for innovation at the interface between industry and the social sector. The sponsorship programs are focused on people - their commitment to public welfare, their wealth of ideas in fulfilling social needs, as well as those that arise in times of emergency. The foundation's funding activities are a central element of Bayer's global social commitment amounting to approximately EUR 50 million annually - with the focus on promoting scientific education and leading-edge research, and on providing health care and meeting the basic social needs of people who live near the company's sites.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


Tel: +49 214 30-39239

Fax: +49 214 30-58923

Email: sonja.diewerge@bayer.com

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
09/22BAYER : Receives Positive CHMP Opinion for Its Hemophilia a Treatment BAY94-9027
09/22BAYER : Jivi Approved in Japan for Hemophilia a
09/21BAYER : collaborates with One Acre Fund to support smallholders in Africa with a..
09/20BAYER : "Fungicidal Compositions And Methods" in Patent Application Approval Pro..
09/20MONSANTO : Patent Issued for Plants And Seeds Of Hybrid Corn Variety CH624975 (U..
09/20BAYER : Compugen earns $7.8m payment from Bayer
09/20MONSANTO : Patent Application Titled "Containerized Liquid Formulations" Publish..
09/20MONSANTO : Patent Issued for Plants And Seeds Of Hybrid Corn Variety CH895408 (U..
09/20MONSANTO : Patent Issued for Soybean Variety 01067507 (USPTO 10,070,616)
09/20MONSANTO : Patent Issued for Soybean Variety 01063975 (USPTO 10,070,617)
More news
News from SeekingAlpha
09/21Feds looking into free services from drug makers - WSJ 
09/21Bayer's Jivi OK'd in Japan for hemophilia A 
09/20Compugen receives milestone payment in cancer immunotherapy collaboration wit.. 
09/19Bayer steps up legal fight over weedkiller, asks court to toss $289M jury awa.. 
09/18AbbVie used kickbacks to boost Humira sales - CA insurance commissioner 
Financials (€)
Sales 2018 39 117 M
EBIT 2018 7 261 M
Net income 2018 4 971 M
Debt 2018 39 658 M
Yield 2018 3,70%
P/E ratio 2018 15,10
P/E ratio 2019 14,12
EV / Sales 2018 2,84x
EV / Sales 2019 2,28x
Capitalization 71 359 M
Duration : Period :
Bayer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 102 €
Spread / Average Target 33%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-25.23%83 828
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092